Thursday, November 16, 2017 5:48:54 AM
6/5/14 Boy how things change.
Pmcb was mid to high .20’s then. We all know now pmcb is nothing but your regular otc scam.
“trials P2B will start as soon as SGAustria gets the GMP compliant facilities up and running
the cell encapsulation equipment has been moved from Singapore to Thailand . this process has been ongoing for a few months , i expect 2014 the facility will be ready to encapsulate cells , fill viles, and send to CT sites . SGAustria designed and built our one off encapsulation equipment at cost ~$8MM
Patient enrollment will be fast with our CRO handling this function
cell bank ready Inno Biologics and ViruSiure
all the pcs are coming together nicely
orphan status , fast track , breakthrough , Grants
Nuvilex stock price will move on up , then we can negoatiate sales of stock with institutional and private investors ~at the market~
say $0.50 to $1.00 / sh prior to P2B
post successful P2B we are the Gold and we're talking Dollars $
then there is vonHoff , whose studies are beginning within weeks
Nuvilex IR believes P2B will begin 1stQ 2015”
Pmcb was mid to high .20’s then. We all know now pmcb is nothing but your regular otc scam.
“trials P2B will start as soon as SGAustria gets the GMP compliant facilities up and running
the cell encapsulation equipment has been moved from Singapore to Thailand . this process has been ongoing for a few months , i expect 2014 the facility will be ready to encapsulate cells , fill viles, and send to CT sites . SGAustria designed and built our one off encapsulation equipment at cost ~$8MM
Patient enrollment will be fast with our CRO handling this function
cell bank ready Inno Biologics and ViruSiure
all the pcs are coming together nicely
orphan status , fast track , breakthrough , Grants
Nuvilex stock price will move on up , then we can negoatiate sales of stock with institutional and private investors ~at the market~
say $0.50 to $1.00 / sh prior to P2B
post successful P2B we are the Gold and we're talking Dollars $
then there is vonHoff , whose studies are beginning within weeks
Nuvilex IR believes P2B will begin 1stQ 2015”
Disclosure: I am involved in and support the SEC whistleblower program, I may be rewarded cash for information that leads to the successful enforcement by the SEC of a federal court or administrative action of 1m+.
Recent PMCB News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:17:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:17:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:17:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:16:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 08:19:59 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 03/17/2026 07:49:54 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/09/2026 01:40:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/09/2026 10:02:46 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/27/2026 10:05:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/07/2026 10:43:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/07/2026 10:43:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/18/2025 10:04:23 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 12/15/2025 09:00:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/12/2025 10:07:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2025 10:00:25 PM
- PharmaCyte Biotech stock surges following profitable exit from Femasys investment • IH Market News • 11/25/2025 03:56:47 PM
- PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment • Business Wire • 11/25/2025 02:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/18/2025 09:32:29 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/18/2025 09:05:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 08:05:33 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/06/2025 09:08:43 PM
